Universitaetsklinikum Erlangen AöR
Universitaetsklinikum Erlangen AöR is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
A Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
Long-term follow-up of patients treated with GD2IL18CART
Sponsor Universitaet Muenster
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH)
Sponsor Philipps-Universitaet Marburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients undergoing chemotherapy to prevent chemotherapy-induced polyneuropathy (CIPN), to reduce symptoms typical of CIPN and to improve the quality of life of patients with CIPN
Sponsor Wala-Heilmittel GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor‑positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin
Sponsor ITM Solucin GmbH
- Start (EU)
- Latest update
- Estimated end
A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Sponsor ITM Solucin GmbH
- Start (EU)
- Latest update
- Estimated end
Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT -
Sponsor Philipps-Universitaet Marburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
COMparison of B-cell dePletion by rituximAb and anti-CD 19 CAR-T therapy in patients with rhEumatoid arthritis- The COMPARE TRIAL TWO - STAGE INTERVENTIONAL, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN LABEL, PARALLEL - GROUP PHASE I/II TRIAL IN PATIENTS WITH ACTIVE, ACPA – POSITIVE AND TREATMENT REFRACTORY RHEUMATOID ARTHRITIS
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis: A two-stage interventional, prospective, open-label, phase I/II trial in patients with active, treatment refractory, ANCA-IgG-positive vasculitis
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitaetsklinikum Erlangen AöR?
The 2026-10-09 snapshot links Universitaetsklinikum Erlangen AöR to 15 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, Safety reporting & pharmacovigilance, Investigational Medicinal Product Manufacturer, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsklinikum Erlangen AöR?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Cardiology, Gastroenterology, Gynecology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsklinikum Erlangen AöR conducted?
The linked trials record locations in 18 countries, including Germany, Spain, France, Italy, Austria. These are trial locations, not confirmed office locations or countries where Universitaetsklinikum Erlangen AöR delivered services.
What can this page tell me about Universitaetsklinikum Erlangen AöR's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsklinikum Erlangen AöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsklinikum Erlangen AöR